Timeline showing the most recent (2006 onwards) key data from prospective clinical trials regarding the efficacy of deferasirox and deferiprone in patients with transfusion-dependent anemias. The original studies are reviewed and listed in Musallam and Taher.4 DFO indicates deferoxmaine; DFX, deferasirox; DFP, deferiprone; LIC, liver iron concentration; LVEF, left-ventricular ejection fraction; RVEF, right-ventricular ejection fraction; TM, β-thalassemia major; SCD, sickle cell disease; and MDS, myelodysplastic syndromes.
